Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$130000.0.

  • Lineage Cell Therapeutics' Change in Receivables fell 17692.31% to -$130000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$278000.0, marking a year-over-year decrease of 71764.71%. This contributed to the annual value of -$106000.0 for FY2024, which is 12376.68% down from last year.
  • Lineage Cell Therapeutics' Change in Receivables amounted to -$130000.0 in Q3 2025, which was down 17692.31% from $43000.0 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Change in Receivables peaked at $753000.0 during Q4 2021, and registered a low of -$50.3 million during Q1 2022.
  • Moreover, its 5-year median value for Change in Receivables was $43000.0 (2025), whereas its average is -$2.6 million.
  • In the last 5 years, Lineage Cell Therapeutics' Change in Receivables tumbled by 3737481.48% in 2022 and then surged by 291666.67% in 2024.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Change in Receivables stood at $753000.0 in 2021, then plummeted by 114.34% to -$108000.0 in 2022, then surged by 382.41% to $305000.0 in 2023, then dropped by 23.61% to $233000.0 in 2024, then tumbled by 155.79% to -$130000.0 in 2025.
  • Its Change in Receivables stands at -$130000.0 for Q3 2025, versus $43000.0 for Q2 2025 and -$424000.0 for Q1 2025.